| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892
MCF-7 human breast cancer cells, grown in long-term tissue culture, were found to be highly responsive to prolactin in terms of growth even in the presence of serum. Human prolactin, placental lactogen, and growth hormone (50–250 ng/ml) stimulated MCF-7 cells to grow when added to culture medium of cells in the presence of charcoal-stripped serum. Within 3 days of the hormone addition, a 4.4-fold increase in cell number was achieved with human prolactin at 100 ng/ml in the presence of 10% charcoal-stripped serum. Under these same conditions, estradiol-17ß at 10-8 M achieved only a 2-fold increase. After 6 days of culture, both estradiol-17ß and prolactin gave a total 5-fold increase in cell number. No prolactin effect was achieved in the presence of 10% fetal bovine serum. Stripping fetal bovine serum with dextran-coated charcoal removes as much as 85% of the endogenous lactogens. Removal of these hormones is essential for demonstration of subsequent prolactin-induced growth response in MCF-7 cells, since bovine prolactin binds effectively to lactogen receptors on the surface of the cells but does not transmit a growth signal. When added simultaneously with human prolactin, bovine prolactin blocks the growth response to the former hormone. These results clearly demonstrate that, under the proper conditions of culture, the human breast cancer cell line MCF-7 is highly responsive to growth stimulation by homologous lactogenic hormones. This then affords us an excellent model for further studies on the possible role of prolactin in growth and maintenance of human breast cancer.
1 To whom requests for reprints should be addressed, at National Cancer Institute, NIH, Building 10, Room 5B56, Bethesda, MD 20892.
Received 3/14/86. Revised 1/12/87. Revised 3/30/87. Accepted 4/ 7/87.
This article has been cited by other articles:
|
|
 |
|
  Y. Fujinaka, K. Takane, H. Yamashita, and R. C. Vasavada Lactogens Promote Beta Cell Survival through JAK2/STAT5 Activation and Bcl-XL Upregulation J. Biol. Chem., October 19, 2007; 282(42): 30707 - 30717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. N. Lauber and N. J. Gooderham The Cooked Meat Derived Genotoxic Carcinogen 2-Amino-3-Methylimidazo[4,5-b]Pyridine Has Potent Hormone-Like Activity: Mechanistic Support for a Role in Breast Cancer Cancer Res., October 1, 2007; 67(19): 9597 - 9602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Neilson, J. Zhu, J. Xie, M. G. Malabarba, K. Sakamoto, K.-U. Wagner, R. A. Kirken, and H. Rui Coactivation of Janus Tyrosine Kinase (Jak)1 Positively Modulates Prolactin-Jak2 Signaling in Breast Cancer: Recruitment of ERK and Signal Transducer and Activator of Transcription (Stat)3 and Enhancement of Akt and Stat5a/b Pathways Mol. Endocrinol., September 1, 2007; 21(9): 2218 - 2232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F E Utama, M J LeBaron, L M Neilson, A S Sultan, A F Parlow, K-U Wagner, and H Rui Human prolactin receptors are insensitive to mouse prolactin: implications for xenotransplant modeling of human breast cancer in mice. J. Endocrinol., March 1, 2006; 188(3): 589 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Goffin, S. Bernichtein, P. Touraine, and P. A. Kelly Development and Potential Clinical Uses of Human Prolactin Receptor Antagonists Endocr. Rev., May 1, 2005; 26(3): 400 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Binart, P. Imbert-Bollore, N. Baran, C. Viglietta, and P. A. Kelly A Short Form of the Prolactin (PRL) Receptor Is Able to Rescue Mammopoiesis in Heterozygous PRL Receptor Mice Mol. Endocrinol., June 1, 2003; 17(6): 1066 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-L. Carsol, S. Gingras, and J. Simard Synergistic Action of Prolactin (PRL) and Androgen on PRL-Inducible Protein Gene Expression in Human Breast Cancer Cells: A Unique Model for Functional Cooperation between Signal Transducer and Activator of Transcription-5 and Androgen Receptor Mol. Endocrinol., July 1, 2002; 16(7): 1696 - 1710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Villablanca, K. A. Lewis, and J. C. Rutledge Time- and dose-dependent differential upregulation of three genes by 17beta -estradiol in endothelial cells J Appl Physiol, March 1, 2002; 92(3): 1064 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Xu, W. Xia, R. Z. Luo, H. Peng, S. Zhao, J. Dai, Y. Long, L. Zou, W. Le, J. Liu, et al. The Human ARHI Tumor Suppressor Gene Inhibits Lactation and Growth in Transgenic Mice Cancer Res., September 1, 2000; 60(17): 4913 - 4920. [Abstract] [Full Text]
|
|
|
|
|
|
R. Nanbu-Wakao, Y. Fujitani, Y. Masuho, M.-a. Muramatu, and H. Wakao Prolactin Enhances CCAAT Enhancer-Binding Protein-{beta} (C/EBP{beta}) and Peroxisome Proliferator-Activated Receptor {gamma} (PPAR{gamma}) Messenger RNA Expression and Stimulates Adipogenic Conversion of NIH-3T3 Cells Mol. Endocrinol., February 1, 2000; 14(2): 307 - 316. [Abstract] [Full Text]
|
|
|
|
|
|
R. C. H. Lee, J. A. Walters, M. E. Reyland, and S. M. Anderson Constitutive Activation of the Prolactin Receptor Results in the Induction of Growth Factor-independent Proliferation and Constitutive Activation of Signaling Molecules J. Biol. Chem., April 9, 1999; 274(15): 10024 - 10034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bole-Feysot, V. Goffin, M. Edery, N. Binart, and P. A. Kelly Prolactin (PRL) and Its Receptor: Actions, Signal Transduction Pathways and Phenotypes Observed in PRL Receptor Knockout Mice Endocr. Rev., June 1, 1998; 19(3): 225 - 268. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Reynolds, K. T. Montone, C. M. Powell, J. E. Tomaszewski, and C. V. Clevenger Expression of Prolactin and Its Receptor in Human Breast Carcinoma Endocrinology, December 1, 1997; 138(12): 5555 - 5560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Ormandy, R. E. Hall, D. L. Manning, J. F. R. Robertson, R. W. Blamey, P. A. Kelly, R. I. Nicholson, and R. L. Sutherland Coexpression and Cross-Regulation of the Prolactin Receptor and Sex Steroid Hormone Receptors in Breast Cancer J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3692 - 3699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C J Ormandy, A Camus, J Barra, D Damotte, B Lucas, H Buteau, M Edery, N Brousse, C Babinet, N Binart, et al. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes & Dev., January 15, 1997; 11(2): 167 - 178. [Abstract] [PDF]
|
|
|
|
|
|
G. Fuh and J. A. Wells Prolactin Receptor Antagonists That Inhibit the Growth of Breast Cancer Cell Lines J. Biol. Chem., June 2, 1995; 270(22): 13133 - 13137. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
